33 research outputs found
Contribuição da quimioembolização de hepatocarcinomas em pacientes cirróticos na espera pelo transplante hepático
Analysis of the immunohistochemical expressions of p53, bcl-2 and Ki-67 in colorectal adenocarcinoma and their correlations with the prognostic factors
Morphofunctional malignancy grading is a valuable prognostic factor for colorectal cancer
Estudo clínico-patológico, da proliferação celular e da apoptose no adenocarcinoma gástrico da cárdia
Qualidade de vida do paciente com câncer colorretal em quimioterapia ambulatorial
Trata-se de um estudo transversal com abordagem quantitativa descritiva, no qual buscou-se avaliar a qualidadede vida (QV) do paciente com câncer colorretal em quimioterapia ambulatorial. A pesquisa foi desenvolvida emuma Unidade de Quimioterapia Ambulatorial em um hospital do sul do Brasil, cujos pacientes eram portadores dodiagnóstico de câncer colorretal e foram submetidos ao tratamento com o Protocolo 5FU. A amostra contou com48 participantes que estavam em tratamento quimioterápico por um período de seis meses. Utilizou-se comoinstrumento um questionário, o WHOQOL-Bref. Nos resultados encontrados, prevaleceu a idade de 50 anos oumais e possuíam no mínimo um mês e no máximo 11 meses de tratamento. Os domínios do WHOQOL-Brefafetados mais significativamente foram o psicológico e o das relações sociais, respectivamente, havendo diferençanas respostas quanto à QV geral naqueles que estavam no 1º ciclo de tratamento daqueles que já se encontravam no6º ciclo
Are high initial CEA and CA 19–9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer?
In certain cell culture studies, significant CEA expression was observed in K-ras mutant cells. However, the relationship between high CEA levels and K-ras status has not been sufficiently investigated. In the present study, we aimed to determine the prognostic role of initial CEA and CA 19-9 values in metastatic colorectal cancer patients according to the status of K-ras. Between 2000 and 2010, a total of 215 patients with metastatic colorectal cancer who were treated and followed up in our oncology center were analyzed. Smokers were excluded from the study. The clinicopathological findings and initial CEA and CA19-9 values were determined. K-ras mutation analysis was performed using quantitative PCR evaluation of the DNA from the tumor tissues. Eighty-two patients (38.1 %) were female and 133 (61.9 %) were male, with a median age of 59 years (range 27-83). Based on tumor localization, 127 patients (59 %) were classified as colon cancer patients and 88 patients (41 %) were classified as rectal cancer patients. The majority of patients (83.3 %) had pure adenocarcinoma histology, while 36 cases (16.7 %) had mucinous adenocarcinoma. The initial CEA levels were detected to be high (> 5 ng/mL) in 108 of the patients (50.2 %), while high levels of initial CA 19-9 (> 37 ng/mL) were found in 90 patients (41.8 %). K-ras mutations were detected in 99 of the patients (46 %). K-ras was found to be wild type in 116 patients (54 %). Significant differences were detected between the K-ras wild-type and mutant groups with respect to age and the initial serum CEA levels. Patients with K-ras mutations were younger (p = 0.04) and had higher initial CEA levels (p = 0.02) compared to patients with K-ras wild type. The median overall survival (OS) time and 3-year OS rate for patients with a high initial CEA level (> 5 ng/mL) were significantly shorter than those of patients with a low initial CEA level ( 37 ng/mL) (37.6 months and 55.7 %, p = 0.04). Multivariate analysis indicated that stage at the time of diagnosis (p < 0.001) and low initial serum CEA level (p = 0.037) were independent prognostic factors of OS. For K-ras mutant patients, the stage at diagnosis (p = 0.017), low initial serum CEA level (p = 0.001), and low initial serum CA 19-9 level were found to be independent prognostic indicators of OS. Our findings demonstrate for the first time that the presence of a K-ras mutation correlated with high initial CEA and CA 19-9 levels in patients with metastatic colorectal cancer. Patients with high initial CEA and CA 19-9 levels may potentially predict the presence of a K-ras mutation, and this prediction may guide targeted therapies in these patients